Olimel N12 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N12 provides a balanced amino acid composition for patients requiring parenteral nutrition support.

• Critical illness: helps maintain nitrogen balance and supports tissue repair in intensive care patients.
• Post‑operative recovery: supplies essential amino acids to promote wound healing after major surgery.
• Severe malnutrition: delivers a complete amino acid profile when oral intake is insufficient.
• Chronic kidney disease: provides essential amino acids while limiting nitrogen load for renal‑compromised patients.

• The amino acids in Olimel N12 are directly incorporated into protein synthesis pathways, replenishing essential building blocks needed for cellular repair, immune function, and metabolic processes. By supplying a balanced profile, the formulation restores nitrogen balance, stimulates anabolic signaling (e.g., mTOR activation), and supports gluconeogenesis and energy production in patients unable to obtain adequate nutrition orally.

Amino acid formulations may be associated with certain adverse reactions.

Common Side Effects

• Nausea or vomiting: mild gastrointestinal discomfort during or after infusion.
• Hyperglycemia: transient rise in blood glucose, especially in diabetic patients.
• Electrolyte disturbances: mild shifts in potassium, calcium, or magnesium levels.
• Infusion site reactions: erythema, warmth, or mild pain at the catheter site.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Metabolic acidosis: significant pH imbalance in susceptible individuals.
• Hepatic dysfunction: elevated liver enzymes indicating liver stress.
• Renal impairment: worsening kidney function in patients with pre‑existing disease.
• Severe electrolyte imbalance: dangerous hyper‑ or hypo‑kalemia or calcium disturbances.
• Thrombophlebitis: inflammation and clot formation at the infusion site.

When using Olimel N12, consider the following safety measures.

• Renal function: assess kidney status before initiation and monitor during therapy.
• Hepatic function: evaluate liver enzymes in patients with liver disease.
• Electrolyte balance: correct pre‑existing abnormalities prior to infusion.
• Blood glucose: monitor closely in diabetic or hyperglycaemic patients.
• Allergy history: verify no known hypersensitivity to any amino acid component.
• Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Amino acid mixtures can interact with other intravenous solutions and systemic therapies.

Major Interactions (Avoid)

• High‑dose glucose solutions: may exacerbate hyperglycaemia when co‑administered.
• Potassium‑rich fluids: increase risk of hyperkalaemia.
• Calcium‑containing solutions: potential for precipitation and reduced efficacy.

Moderate Interactions (Monitor Closely)

• Diuretics: may amplify electrolyte shifts; monitor serum levels.
• Insulin therapy: adjust insulin dosage due to glucose load from the formulation.
• Renal replacement therapy: may alter amino acid clearance, requiring dose adjustments.